| Literature DB >> 35600854 |
Julie Frigaard1, Janicke Liaaen Jensen1, Hilde Kanli Galtung2, Marianne Hiorth3.
Abstract
The unique properties and applications of nanotechnology in targeting drug delivery, cosmetics, fabrics, water treatment and food packaging have received increased focus the last two decades. The application of nanoparticles in medicine is rapidly evolving, requiring careful investigation of toxicity before clinical use. Chitosan, a derivative of the natural polysaccharide chitin, has become increasingly relevant in modern medicine because of its unique properties as a nanoparticle. Chitosan is already widely used as a food additive and in food packaging, bandages and wound dressings. Thus, with an increasing application worldwide, cytotoxicity assessment of nanoparticles prepared from chitosan is of great interest. The purpose of this review is to provide an updated status of cytotoxicity studies scrutinizing the safety of chitosan nanoparticles used in biomedical research. A search in Ovid Medline from 23 March 1998 to 4 January 2022, with the combination of the search words Chitosan or chitosan, nanoparticle or nano particle or nanosphere or nanocapsule or nano capsule, toxicology or toxic or cytotoxic and mucosa or mucous membrane resulted in a total of 88 articles. After reviewing all the articles, those involving non-organic nanoparticles and cytotoxicity assays conducted exclusively on nanoparticles with anti-tumor effect (i.e., having cytotoxic effect) were excluded, resulting in 70 articles. Overall, the chitosan nanoparticles included in this review seem to express low cytotoxicity regardless of particle composition or cytotoxicity assay and cell line used for testing. Nonetheless, all new chitosan derivatives and compositions are recommended to undergo careful characterization and cytotoxicity assessment before being implemented on the market.Entities:
Keywords: cell viability; chitosan; cytotoxicity; drug carriers; drug delivery systems; nanocapsule; nanoparticles
Year: 2022 PMID: 35600854 PMCID: PMC9115560 DOI: 10.3389/fphar.2022.880377
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
FIGURE 1The conversion of chitin to chitosan by N-deacetylation.
FIGURE 2(A) Nanosphere composed of chitosan (blue) with crosslinkers (red), (B) Liposome (green) with chitosan coating (blue), (C) Chitosan nanoparticle (blue) covered with other substance (light brown) such as proteins or polymers, (D) Nanocapsule made of chitosan (blue).
Articles on chitosan nanoparticles with TPP as crosslinker, main findings.
| Chitosan characteristics | Nanoparticle composition | Active ingredient | Cell line/Species | Toxicity assay | Cytotoxicity results | References |
|---|---|---|---|---|---|---|
| Chitosan 80 kDa DDA ∼85% | Chitosan/TPP/MgSO4/poly-ɣ-glutamic acid | Insulin | Adult ICR mice | Clinical hematological biochemical histology | The unloaded NPs were well tolerated. |
|
| Chitosan low MW DDA 85% | Chitosan/TPP | Hydrochlorothiazide (HCT) | Intestinal gut sac from wistar male rats | Histology | HCT-loaded NPs showed less prominent changes than free HCT. |
|
| Chitosan ∼50 kDa DDA 86% | Chitosan/TPP | Rosmarinic acid, salvia officinalis (sage) and satureja montana (savory) | ARPE-19 | MTT assay LDH assay HET-CAM | Rosmarinic acid-, Saliva officinalis- and Satureja montana loaded NPs: LDH assay: LDH assay: <10% cytotoxicity, MTT-assay: Non-toxic for concentrations <1 mg/ml, HET-CAM: Non-irritating. |
|
| Chitosan low MW DDA ≥75% | Chitosan/TPP, coated with retrograded soluble starch or retrograded high amylose corn starch | Doxorubicin and neutraceutical-coagulants | Caco-2 cells | CCK-8 kit | Unloaded NPs had no effect on cell viability after 2 h, 10%–15% cell death after 24 h. |
|
| Chitosan DDA 95% | Chitosan/TPP/carrageenan | Resveratrol, coumarin-6 | Caco-2 cells | MTT assay | Resveratrol-loaded NPs showed >90% cell viability for all sizes (200–1,000 nm). |
|
| Chitosan low MW | Chitosan/TPP | Inactivated influenza virus | Calu-6 cells | XTT assay | Unloaded dry-powder chitosan nanoparticles of 50, 250, and 500 µg/ml showed concentration dependent cell viability, from 100 to 70% after 2 h, and 60%–20% after 24 h. |
|
| Chitosan Hydrochloride DDA 91.1% | Chitosan/TPP | Thymopentin | Caco-2 cells | MTT assay | Unloaded NPs showed 80%–90% viability in all tested concentrations (0.25, 0.5, 1.0, 1.5 and, 2.0 mg/ml) after 4 h. |
|
| Chitosan oligosaccharide ∼3 kDa DDA 90% | Chitosan/TPP | Herring sperm DNA | Calu-3 cells | MTT assay | The cell viability of DNA-loaded chitosan nanoparticles were >70% up to 2 mg/ml after 48 h of incubation. |
|
| Chitosan low MW | Chitosan/TPP | Human gingival fibroblasts from retromolar tissue | MTS assay LDH assay | Unloaded NPs (100, 300, and 600 µg/ml) did not induce cytotoxic effect, but rather stimulates cell viability and promotes cell proliferation. |
| |
| Chitosan low MW | Chitosan/TPP Chitosan/TPP/Hyaluronic acid | J774.2 cells L929 cells | MTT assay LIVE/DEAD Fluorimetri c assay | All NPs ≤0.1 mg/ml showed >80% cell viability for both cell lines. The hyaluronic acid loaded NPs showed higher cell viability than unloaded NPs. |
| |
| Chitosan low MW | Chitosan/TPP | Human gingival fibroblasts from retromolar tissue | LDH assay MTS assay | Unloaded NPs showed no cytotoxicity up to 1 mg/ml, reduced cell viability was seen at 5 mg/ml. |
| |
| Chitosan medium MW DDA ∼79% | Chitosan/TPP | Bi-potential human liver cells (BHAL) | MTT assay | NPs showed >90% cell viability at pH 7.4 for concentrations up to 1.0% for 4 h, and >70% for 0.5% for 24 h. At pH 6 the cell viability was >90% for 0.1% for both 4 and 24 h. |
| |
| Chitosan medium MW | Chitosan/TPP | Caco-2 cells | MTT assay | NPs showed >80% cell survival at pH 7.4 for concentrations up to 0.1% for 4, 24, 48, and 72 h. For pH 6.4 > 70% survival for 0.025% up to 24 h, and >80% survival for 0.05% up to 48 and 72 h. |
| |
| Chitosan chloride ∼213 kDa | Chitosan/TPP | Ovalbumin | Caco-2 cells | MTS assay LDH assay | MTS assay: Ovalbumin-loaded NPs showed 62% cell viability at 0.1 mg/ml, while 0.05 mg/ml had a reduction of 15%. LDH assay: No cytotoxicity detected for Ovalbumin loaded NPs. |
|
| Chitosan medium MW< DDA 75%–85% | Chitosan/TPP | Carboxylated 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY-COOH) | A549 cells BEAS 2B cells | MTT assay | Unloaded NPs were non-cytotoxic for both cell types, for all concentrations (0.5, 1, 2, 5, 10, 25 and, 50 µg/ml). |
|
| Chitosan 404.7 KDa DDA 76% | Chitosan/TPP | Doxorubicin | HT-1197 cells | MTT assay | Unloaded NPs showed no significant decline in cell viability for concentrations ranging from 0,01 to 10 µg/ml. |
|
| Chitosan chloride MW 307 kDa DDA 83% | Chitosan/TPP | TR146 cells | MTT assay | NPs showed 80% cell viability, and was less cytotoxic than free chitosan. |
| |
| Chitosan Hydrochloride DDA 86% | Chitosan/TPP/mannitol | Calu-3 cells A549 cells | MTT assay | Cell viability >80% for all concentrations of NPs (0.001, 0.01, 0.1, 1, 10 mg/ml). |
| |
| Chitosan chlorhydrate | Chitosan/TPP | Quetiapine fumarate | Goat nasal mucosa | Histology | No observation of cell necrosis or structural damage on nasal mucosa 1 h after administration of quetiapine-fumarate loaded NPs |
|
| Chitosan DDA 85% | Chitosan/TPP | ATCC CCL 20.2 cells | Trypan Blue SEM | All NP concentrations (0.25, 0.5, 1.0, 2.0 mg/ml) showed >90% viability. SEM showed abundant microvilli and intact membrane details for ≤1.0 mg/ml, for 2 mg/ml a few small membrane holes, some degree of cell flattening and microvilli loss were observed |
| |
| Chitosan | Chitosan/TPP | Rotigotine | Goat nasal mucosa | Histology | The Rotigotine-loaded NPs produced no toxicity or structural damage to nasal mucosa after 24 h. |
|
| Chitosan DDA 95% | Chitosan/Tripolyphosphate Chitosan/Phytic acid Chitosan/Sodium hexametaphosphate | Myricetin | Caco-2 cells | MTS assay | Myricetin-loaded NPs showed >90% cell viability for NPs after 24 h for both concentrations (10 and 20 µg/ml). |
|
| Chitosan | Chitosan/TPP Chitosan/TPP/eudragit | UCN 01 (potent caspase 3 activator) | Caco-2 cells | MTT assay LIVE/DEAD stain | Unloaded NPs showed higher cell viability compared to eudragit-loaded NPs, with >80% cell viability for all concentrations tested (up to 0.5 µM). |
|
| Chitosan | Chitosan/TPP | Hepatitis E capsid protein p146 | L929 fibroblasts | MTT assay | All concentrations of p146-loaded NPs (0–2 mg ml−1) showed >80% viability after 24 h. |
|
| Chitosan | Chitosan/TPP | Gastric tissue from Wistar rats | Macroscopic Histology | Observations indicated that the gastric toxic effects of cadmium chloride were reduced by NPs at 600 mg/kg BW. |
|
Articles on chitosan nanoparticles without TPP as crosslinker, main findings.
| Chitosan characteristics | Nanoparticle composition | Active ingredient | Cell line/species | Toxicity assay | Cytotoxicity results | References |
|---|---|---|---|---|---|---|
| Chitosan DDA 95% | Chitosan/Na2SO4 and Chitosan/Na2SO4/alginate | Ovalbumin | Spleen cells from female BALB/c mice | MTT assay Trypan blue PI stain | No cytotoxicity was detected for any of the unloaded NPs (0.28 and 0.42 mg/ml), on the contrary increased proliferation was observed |
|
| Chitosan low MW DDA 95% | Chitosan/Na2SO4 | C48/80 (mast cell activator) | Spleen cells from C57BL/6 mice A549 cell line | MTT assay | Spleen cells: >80% cell viability when incubated with unloaded NPs ≤1.08 mg/ml. A549 cell line: >70% cell viability when incubated with unloaded NPs ≤1.5 mg/ml |
|
| Chitosan 71.3 kDa DDA 80% | Chitosan/Na2SO4 | Newcastle disease virus F gene DNA (pFNDV) | SPF chickens 293-T cells (chicken embryo kidney cellsCEK cells) | Safety test WST-8 kit | Intranasal administration of pFNDV loaded-NPs considered safe. 84% survival rate of kidney cells, no significant changes in cell morphology |
|
| Chitosan 200–300 kDa DDA 85% | Chitosan/mucin | Insulin | Wistar rats | Liver enzymes MTT assay |
|
|
|
| ||||||
| Chitosan | Chitosan | Chitosan Thymol (2-isopropyl-5- ethylphenol | Nile tilapia fingerlings | Biochemical Macroscopic Histologic | No significant change in survival rate between experimental groups when fed with unloaded and Thymol-loaded NPs. |
|
Articles on chitosan nanoparticles in combination with liposomes, main findings.
| Chitosan characteristics | Nanoparticle composition | Active ingredient | Cell line/species | Toxicity assay | Cytotoxicity results | References |
|---|---|---|---|---|---|---|
| Chitosan low MW | Chitosan/lipid | Cisplatin | A2780 cells | Cell Titer Blue assay | Unloaded NPs showed approximately 100% cell viability up to 6.2 µg/ml. |
|
| Chitosan hydrochloride | Chitosan/SoyPC/EggPG | TR146 cell line | MTS/PMS assay | NPs reduced cell viability of proliferating cells to approximately 10% viability, the cell viability of the stratified cells was around 40%. |
| |
| Chitosan MW 3.1 × 105 DDA 83% | Chitosan/SoyaPC/EggPG | HT29-MTX cell-line | MTT assay Permeation of paracellular marker | NPs showed high degree of biocompatibility and low toxicity in both confluent monolayer and cells in exponential growth. |
| |
| Chitosan 80kD DDA 80% | Chitosan/DOPG/DOPE | Anti-caries DNA vaccine (pGJA-P/VAX) | RAW 264.7 cells Female Balb/c mice | MTT assay Fluorescence imaging | DNA-loaded NPs showed >70% cell viability for concentrations up to 60 µg/ml. |
|
| Chitosan hydrochloride | Chitosan/TPP Chitosan/TPP/DSPC/DPPS/CHOL Chitosan/TPP/DSPC/CHOL Chitosan/TPP/DPPS/CHOL | IOBA-NHC cells Female albino New Zealand Rabbit eyeball and lid tissues | XXT assay Macroscopic Histology Cytology | Chitosan NPs showed cell viability >70% for all concentrations (0.25, 0.5, and 1 mg/ml) and incubation times (15, 30 and 60 min), except for 1 mg/ml at 15 min (recovery after 15 min). |
| |
| All liposome-chitosan-NPs showed higher cell viability than chitosan NPs. Chitosan NPs and liposomes-chitosan NPs both showed good tolerance |
FIGURE 3Fluorescence detected in mice after intranasal administration of Cy5.5-marked anionic liposome/chitosan/DNA nanoparticles at different time intervals. Figure adopted from Chen et al. (2013) (https://creativecommons.org/licenses/by/4.0/).
Articles on nanoparticles coated with chitosan, main findings.
| Chitosan characteristics | Nanoparticle composition | Active ingredient | Cell line/species | Toxicity assay | Cytotoxicity results | References |
|---|---|---|---|---|---|---|
| Chitosan medium MW DDA 75%–85% | Chitosan/poly (lactic-co-glycolic acid) | Ferulic acid | B16-F10 and HeLa cells | MTT assay | Ferulic acid-loaded NPs showed cell viability 70%–80% for B16-F10 when the concentration was ≤30 µg/ml, and >70% for HeLa cells for up to 60 µg/ml. |
|
| Chitosan 120 kDa DDA >80% | Chitosan/poly (lactic-co-glycolic acid) | Bevacizumab | Briefly fertilized hen’s eggs | HET-CAM | Unloaded NPs (0.5 ml) were found to be non-irritant as well tolerated for ophthalmic use. |
|
| Chitosan DDA 75%–85% | Chitosan/poly (lactic-co-glycolic acid) | 7-ethyl-10-hydroxycamptothecin | Caco-2 cells | WST-1 assay LDH-release | Unloaded NPs showed 100% cell viability for concentrations up to 500 µg/ml. A transient effect on the membrane integrity was observed, in a concentration-dependent fashion, but did not have an influence on cell viability. |
|
| Chitosan | Chitosan/membrane vesicles |
| Adult zebrafish wild type strain AB | Dose-response experiment Histology | No acute toxic effects were detected in the dose-response experiment, but a reduction in activity levels were observed in fish injected with the highest dose of cMVs (40 µg) |
|
| Chitosan | Chitosan modified mPEG2000-b-PCL4000-COOH | Tolbutamide | 293T cells | MTT assay | Unloaded NPs showed >95% cell viability up to 0.25 mg/ml for 24 h |
|
FIGURE 4Schematic representation of carboxymethylated chitosan and its derivatives.
Articles on nanoparticles with carboxymethyl chitosan, main findings.
| Chitosan characteristics | Nanoparticle composition | Active ingredient | Cell line/species | Toxicity assay | Cytotoxicity results | References |
|---|---|---|---|---|---|---|
| Chitosan 50 kDa, DDA 93.15%, 170 kDa, DDA 92.56%, 820 kDa, DDA 90.14% | Oleoyl-carboxymethyl-chitosan | Fluorescein | Caco-2 cells | MTT assay | Unloaded NPs in all tested concentrations (20, 50, 100, 200, 500, 1,000 µg/ml) showed no cytotoxicity. |
|
| Chitosan 50 kDa DDA 93.15% | Oleoyl-carboxymethy-chitosan and Oleoyl-carboxymethy-chitosan/hyaluronic acid | Plasmid DNA | Caco-2 cells | MTT assay | Both DNA-loaded NPs showed >90% cell viability for concentrations up to 200 µg/ml. |
|
| Chitosan medium MW | Carboxymethyl chitosan-2, 2’ ethylenedioxy bis-ethylamine-folate | Vancomycin | NIH 3T3 cells | MTT assay | Unloaded NPs showed no cytotoxicity for concentrations up to 25 µg/ml. |
|
| Chitosan 53.0 kDa DDA 80%–85% | SiO2-Carboxymethyl chitosan-N-2-Hydroxypropyl trimethyl ammonium chloride | Newcastle disease virus | DF-1 cells | CCK-8 assay | Unloaded NPs had an overall survival rate >80% for concentrations up to 1,000 µg/ml. |
|
| Chitosan medium MW | Carboxymethyl chitosan-2, 2’ ethylenedioxy bis-ethylamine-folate | HeLa cells Swiss male mice | MTT assay Acute toxicity |
|
| |
|
| ||||||
| Chitosan medium MW | Carboxymethyl chitosan-2, 2’ ethylenedioxy bis-ethylamine-folate | Swiss male mice | Histology Biochemical | Treatment with NPs 1 mg/kg bw/day for 7 days did not cause any kind of tissue damage, alteration of oxidant-antioxidant status or DNA damage of the experimental group. |
|
Articles on nanoparticles with quaternized chitosan, main findings.
| Chitosan characteristics | Nanoparticle composition | Active ingredient | Cell line/species | Toxicity assay | Cytotoxicity results | References |
|---|---|---|---|---|---|---|
| Chitosan 177 kDa DDA 93% | N-trimethyl chitosan/TPP | Ovalbumin | Calu-3 cells chicken embryo trachea | MTS assay ciliary beat frequency | Unloaded NPs (40 mg/ml) showed >90% cell viability when incubated with Calu-3 cells. Cilio-inhibiting effect: 40% and 80% of the initial value, were seen for unloaded NPs 40 and 8 mg/ml, respectively |
|
| Chitosan 30, 200, 500 kDa DDA 85% | Trimethyl chitosan-cysteine | Insulin | Caco-2 cells ileal loop from rats | MTT assay LDH assay | Unloaded NPs (1 mg/ml) demonstrated absence of toxicity for both MTT-assay for Caco-2 cells, and LDH assay on intestinal content from ileal loop. |
|
| Chitosan 87 kDa DDA 5% | N-(2-hydroxy)-propyl-3-trimethylammonium, O-palmitoyl chitosan (DPCat) | Clotrimazole | HEC-1A endometrial cells CaSki cervical cells HeLa cervical cells | Resazurin assay | Loaded NPs showed >80% cell viability up to 100 µg ml−1 in all cell lines, and reduced cytotoxicity compared to free Clotrimazole. |
|
| Chitosan DDA >95% | N,N,N-trimethyl chitosan chloride (TMC) Alginate-coated TMC (SA-TMC) | Low molecular weight heparin | Male Kunming mice Male SpragueDawley Raw 264.7 macrophages CT26 cells | Histology MTT assay |
|
|
|
| ||||||
| N-2-hydroxypropyl dimethylethyl ammonium chloride chitosan (N-2-HFCC) | N-2-hydroxypropyl dimethylethyl ammonium chloride chitosan/N,O-carboxymethyl chitosan | Newcastle disease virus | Chicken embryonic fibroblast (CEF), 4-week-old SPF chickens | CCK-8 assay Survival rate |
|
|
|
| ||||||
| N-2-hydroxypropyl trimethyl ammonium chloride chitosan and N,O-carboxymethyl chitosan | N-2-hydroxypropyl trimethyl ammonium chloride chitosan, N,O-carboxymethyl chitosan | Newcastle disease virus and infectious bronchitis virus | Chicken embryo fibroblasts (CEF), 14-days-old chickens | Safety test CCK-8 kit |
|
|
|
| ||||||
| Chitosan low MW | N-trimethylaminoethylmethacrylate chitosan/TPP | Ovalbumin | Sprague-Dawley rats, Blood from New Zealand white rabbit | Histology Inflammatory parameters in rats Percentage of hemolysis in rabbits | Loaded NPs (5 and 25 mg/ml) showed no obvious toxicity to nasal mucosa after administration, no induced oxidative stress or inflammatory reaction. Loaded NPs (0.125–2 mg/ml) induced ≤1% hemolysis, indicating that the loaded NPs will not affect the integrity and functionality of erythrocytes in the blood circulation. |
|
Articles on nanoparticles with thiolated chitosan, main findings.
| Chitosan characteristics | Nanoparticle composition | Active ingredient | Cell line/species | Toxicity assay | Cytotoxicity results | References |
|---|---|---|---|---|---|---|
| Chitosan low MW DDA 75%–85% A549 cells | Aminated chitosan and aminated plus thiolated chitosan | Albumin | MTT assay | Unloaded NPs showed cell viability >80% for concentrations up to 1 mg ml−1 in Calu-3 cells, and up to 0.1 mg ml−1 for A549 cells. NPs showed higher cell viability than free polymer. |
| |
| Chitosan low MW DDA 94% | Chitosan- g -Poly (Methyl Methacrylate), thiolated- and unthiolated, crosslinked (TPP) and non-crosslinked (no TPP) | Caco-2 cells HT29-MTX cells (including co-culture model) | MTT assay | Non-crosslinked unthiolated NPs: >80% cell viability of both cell lines, for both concentrations (0.05 and 0.1% w/v) and both times (4 and 24 h), for co-culture model >90%. |
| |
| Non-crosslinked thiolated NPs: Very variable results, large variance, >80% cell viability for 0.05% w/v in Caco-2 cells, reduced cell viability for 0.1% w/v. For HT29-MTX cells >70% cell viability for 0.05 and 0.1% w/v after 4 h, reduced cell viability after 24 h | ||||||
| Chitosan water soluble 20 kDa DDA 92% | Poly (isobutylcyanoacrylate) (PIBCA) | Chitosan, chitosan-4- thiol-butylamidine of different ratios | HeLa cells Caco-2/TC7 cells | Trypan blue | HeLa cells: Unloaded and loaded NPs showed low cell viability due to PIBCA core (no chitosan). |
|
| Caco-2/TC7 cells: Loaded NPs showed >75% cell viability for all ratios up to 50 µg/ml, except 25/75wt% (65%) | ||||||
| HT-29/MTX cells: Loaded NPs showed ≥80% cell viability for all ratios up to 50 μg/ml. | ||||||
| Chitosan 20 kDa DDA 92% | Poly (isobutylcyanoacrylate) (PIBCA) in Pluronic F127 hydrogel | Chitosan, chitosan-4- thiol-butylamidine | Pig vaginal mucosa | Histology | Loaded NPs (75/25 wt%) with concentration 20 mg/ml, did not show any toxicity. |
|
| Chitosan Medium MW DDA 85% | Thiolated chitosan | Centella asiatica | Goat nasal mucosa | Histology MTT assay |
|
|
|
| ||||||
| Chitosan medium MW DDA 89% | Poly methyl methacrylate, coated with chitosan-glutathione | Paclitaxel | NIH 3T3 cells T47D cells HT29 cells Caco-2 cells | MTT assay | Unloaded NPs of all concentrations (up to 20 µg/ml) showed >80% viability for all cell lines. Thiolation of NPs did not increase the cytotoxicity |
|
| Chitosan 60 and 450 kDa | Thiolated chitosan/Sodium alginate | Tizanidine | RPMI 2650 cells | MTT assay | Unloaded NPs up to 40 mg/ml showed no significant toxicity. Thiolation of NPs decreased cytotoxicity. |
|
| Chitosan 400 kDa DDA 70%–80% | Chitosan-6-mercaptonicotinic acid | Insulin | Caco-2 cells | LDH assay | Unloaded NPs (0–100 µg/ml) showed >90% cell viability. Thiolation of the NPs did not increase cytotoxicity. |
|
| Chitosan 400 kDa DDA 70%–85% | Chitosan/TPP/thiobutylamidine | PEG 300, miglyol 840, cremophor EL, caprylic triglyceride | Caco-2 cells | MTT assay LDH assay | Both unloaded and loaded NPs showed >70% viability with both assays. |
|
Articles on other derivatives and complexes with chitosan nanoparticles, main findings.
| Chitosan characteristics | Nanoparticle composition | Active ingredient | Cell line/species | Toxicity assay | Cytotoxicity results | References |
|---|---|---|---|---|---|---|
| Chitosan 3–5 kDa DDA 75% | Chitosan/ceramide | Paclitaxel | B16F10 cells MCF-7 cells | MTT assay | Unloaded NPs showed no cytotoxicity in either cell line for concentrations up 100 µg/ml. |
|
| Chitosan 50–190 kDa DDA 75–85% | Chitosan/curcumin/hypromellose | Curcumin | NCI-N87 cells | MTT assay | Loaded NPs showed 99.7% and 69% cell viability for Curcumin concentrations of 1 and 10 µg/ml, respectively. |
|
| Chitosan 50–190 kDa | Chitosan/curcumin | Curcumin | A549 cells | MTT assay | Loaded NPs showed 95 and 85% cell survival for the two Curcumin concentrations of 0.425 and 0.85 mg/ml, respectively. |
|
| Chitosan 80 kDa DDA 95% | Chitosan/Gadolinium | Gadopentetic acid | HeLa cells Male Sprague-Dawley rats | MTT assay | Loaded NPs showed >80% cell survival when Gadolinium concentration was ≤125 µg/ml, for up to 72 h. Loaded NPs below 14.2 mg/ml, administrated rectally and washed out with water after 120 min, were considered safe. |
|
| Chitosan 50–60 kDa | Hydroxypropyl trimethyl ammonium/Soybean Lecithin/Glyceryl monostearate | Docetaxel | Caco-2 cells, GI mucosa of Sprague-Dawley rats | MTT assay Histology | Blank SLNs, CS-SLNs, HACC-SLNs all showed >80% at concentration range of 0–2,000 µg/ml. HACC-DTC-SLNs had no toxicity on GI mucosa. |
|
| Glycol chitosan 168 kDa | 5β-cholanic acid-modified glycol chitosan | Fluorescein isothiocyanate-labeled dextrans insulin | Male wistar rats | LDH CII assay BCA Protein Assay | Unloaded NPs of 20 mg/ml did not result in any membrane damage to the jejunum 4 h after jejunal administration. |
|
| Chitosan powder DDA 75%–85% | Chitosan/alginate | Lovastatin | Thirty adult Swiss mice | Acute- and subchronic toxicity | After 28 days of loaded NP oral injections (0, 100 and 300 mg/kg) no significant differences were seen in hematological- or biochemical parameters and no abnormal signs or mortality were observed. LD50 was greater than 5,000 mg/kg and considered practically nontoxic. |
|
| Chitosan 310–375 kDa DDA 75% | Chitosan | Hydroxyapatite NPs | Eighty male wistar rats | Biochemical parameters, gene expression of oxidant- and antioxidant parameters histology | The test animals were orally treated with 280 mg/kg bw chitosan NPs for 45 days. The chitosan NP treated group showed overall the same or less toxic results compared to the negative control. No histological alterations in the rat small intestine were detected. When chitosan NPs were administrated in combination with hydroxyapatite NPs, the toxic effect from hydroxyapatite NPs was reduced significantly. |
|
FIGURE 5Histological HE-staining of liver from rats after 28 days of oral treatment with and without Alginate/Chitosan/Lovastatin nanoparticles, in two different concentrations (100 and 300 mg/kg). Figure adopted from Thai et al. (2020) (https://creativecommons.org/licenses/by/4.0/).